Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.470
-0.100 (-6.37%)
At close: Apr 7, 2026, 4:00 PM EDT
1.520
+0.050 (3.40%)
After-hours: Apr 7, 2026, 7:59 PM EDT
Acrivon Therapeutics Employees
As of December 31, 2025, Acrivon Therapeutics had 76 total employees, including 74 full-time and 2 part-time employees. The number of employees decreased by 2 or -2.56% compared to the previous year.
Employees
76
Change (1Y)
-2
Growth (1Y)
-2.56%
Revenue / Employee
n/a
Profits / Employee
-$1,025,066
Market Cap
56.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 76 | -2 | -2.56% | 74 | 2 |
| Dec 31, 2024 | 78 | 17 | 27.87% | 75 | 3 |
| Dec 31, 2023 | 61 | 17 | 38.64% | 58 | 3 |
| Sep 30, 2023 | 59 | 17 | 40.48% | 56 | 3 |
| Jun 30, 2023 | 53 | 17 | 47.22% | 50 | 3 |
| Mar 31, 2023 | 48 | 12 | 33.33% | 45 | 3 |
| Dec 31, 2022 | 44 | - | - | 41 | 3 |
| Sep 30, 2022 | 42 | - | - | 39 | 3 |
| Jun 30, 2022 | 36 | - | - | 35 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| MindWalk Holdings | 102 |
| ImmuCell | 84 |
| Kezar Life Sciences | 55 |
| OnKure Therapeutics | 45 |
| Entera Bio | 22 |
| ImageneBio | 15 |
| Instil Bio | 14 |
ACRV News
- 19 days ago - Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 21 days ago - Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors - GlobeNewsWire
- 6 weeks ago - Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 6 weeks ago - Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress - GlobeNewsWire
- 6 weeks ago - Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - GlobeNewsWire
- 3 months ago - Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls - Benzinga
- 3 months ago - Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - GlobeNewsWire